Search clinical trials for: SHR4640

Total 42 results

Jiangsu HengRui Medicine Co., Ltd.

Completed

Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects

Hyperuricemia

China
Atridia Pty Ltd.

Completed

A Single Dose Study of SHR4640 in Healthy Male Volunteers

Gout

Australia
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects

Hyperuricemia

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers

Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers

Hyperuricemia | Primary Gout
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.

Healthy Adult Male Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Multiple Dose Study of SHR4640 in Healthy Subjects

Gout; Hyperuricemia

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment

Hepatic Impairment

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia

Hyperuricemia
Atridia Pty Ltd.

Completed

Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level

Hyperuricemia | Gout

Australia
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia

Primary Gout and Hyperuricemia
Jiangsu HengRui Medicine Co., Ltd.

Completed

Single Dose Study of SHR4640 in Healthy Subjects

Gout; Hyperuricemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval

Gout and Hyperuricemia

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Relative Bioavailability Study of SHR3680 (SHR-3680)

Healthy Male Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients

Hormone Refractory Prostate Cancer | Metastatic Prostate Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia

Hyperuricemia

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects

Castration-Resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

Prostate Cancer | Castration-resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Prostate Cancer | Castration-resistant Prostate Cancer

China
Atridia Pty Ltd.

Completed

A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer

Prostate Cancer | Neoplasm

Australia
Jiangsu HengRui Medicine Co., Ltd.

Completed

Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

Hyperuricemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout

Gout

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

Hepatic Impairment | Healthy Participants

China
Hospital de Mataró

Completed

Effect Of Piperine In Patients With Oropharyngeal Dysphagia (FIS 2009_2)

Deglutition Disorders

Spain
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

Prostate Cancer Metastatic

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout

Gout

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout

Gout

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)

Healthy Male Subjects

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Prostate Cancer | Biochemical Recurrence

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer

Prostate Cancer | Hormone-Dependent Prostate Cancer

China, Czechia, Poland, Bulgaria
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Prostate Cancer | Biochemical Recurrence

China
Shire

Terminated

Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo

Adenoviral Conjunctivitis

United States, Puerto Rico
Shire

Terminated

Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo

Adenoviral Conjunctivitis

United States, Israel, France, India, Australia, Austria, Spain, Estonia, Hungary, Poland, South Africa, Canada, Germany, Italy, Peru, United Kingdom
Shire

Completed

Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo

Bacterial Conjunctivitis

United States, Australia, Austria, Israel, Poland, Hungary, South Africa, Canada, Estonia, France, Italy, Spain, Puerto Rico
Boehringer Ingelheim

Completed

Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension

Hypertension

Belgium, Canada, Denmark, Finland, France, Korea, Republic of, Netherlands, Norway, Philippines, South Africa, Sweden, Taiwan
Fudan University

Not yet recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

TNBC - Triple-Negative Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion

Prostate Cancer Patients

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride

Drug-drug Interaction,SHR3680

China
Fudan University

Recruiting

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (MULAN)

Breast Cancer | Metastatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole

Prostate Cancer Patients

China
Fudan University

Recruiting

FUSCC Refractory TNBC Umbrella (FUTURE) (FUTURE)

Triple-negative Breast Cancer

China

Search clinical trials for: SHR4640

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations